查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011595

药物安全检测市场：按类型、产品生命週期、给药方式、流程、治疗领域和最终用户划分－2026-2032年全球市场预测

Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，药物安全检测市场价值将达到 118.4 亿美元，到 2026 年将成长至 137.1 亿美元，到 2032 年将达到 341.7 亿美元，年复合成长率为 16.34%。

主要市场统计数据
基准年 2025 118.4亿美元
预计年份：2026年 137.1亿美元
预测年份 2032 341.7亿美元
复合年增长率 (%) 16.34%

对现代药物安全检测面临的关键挑战进行了简要概述，反映了数据的复杂性、不断变化的法规以及组织在安全管治的准备。

药物安全检测处于病人安全、监管和商业性永续性的交汇点。随着治疗方法创新加速发展，真实世界数据（REW）的重要性日益凸显，安全监测模式必须适应更复杂的资料来源、更短的研发週期和更严格的监管审查。本文总结了重塑该领域的关键因素，涵盖资料架构和自动化、人才模式以及跨职能管治等各个面向。

探索正在重新定义药物安全检测实践的关键结构和技术变革，包括人工智慧、真实世界证据和现代监管期望。

药物安全检测领域正经历着由技术创新、监管现代化和策略采购所驱动的变革。人工智慧 (AI) 和机器学习能够透过跨资料集的模式识别，及早发现安全讯号；而自然语言处理则能够更有效地从医疗记录和社交媒体等自由文字来源中提取相关资讯。这些能力与日趋成熟的真实世界资料生态系统相辅相成，使安全团队能够将纵向病患资讯添加到传统的临床试验资料中。

对 2025 年费用修订措施如何重组药物安全检测业务的供应链选择、外包策略和成本管治进行全面评估。

2025年关税上调引发了整个药物安全检测的一系列营运和战略应对措施，影响了供应链、服务采购和成本结构。进口关税的提高推高了某些医疗设备及相关硬体的成本，促使一些机构重新评估其资本累积时机，并考虑在地采购以降低跨境课税风险。这些采购压力间接影响药物安全检测，尤其是在监测工作流程中包含器械主导诊断和第三方安全硬体的情况下。

详细的細項分析揭示了安全调查方法、生命週期阶段、交付模式、流程架构、治疗领域和最终用户概况如何影响药物安全检测的优先事项。

关键细分洞察揭示了基于安全资料收集方法、临床开发阶段、交付模式、流程架构、治疗领域和最终用户类型的不同策略重点。考虑到这些类型，每种方法——队列心臟事件记录器、电子健康记录挖掘、增强型不良反应报告、自愿报告和定向自愿报告——都对数据品质、延迟和检验提出了不同的要求。队列心臟事件记录器和电子健康记录挖掘需要强大的纵向数据整合和高级分析，而自愿报告则强调快速资料撷取和标准化编码工作流程。

区域评估监管、资料基础设施和服务能力方面的区域差异如何促使製定统一的全球标准和在地化的实施策略。

区域趋势对跨辖区营运设计、监管策略和资源分配决策有重大影响。在美洲，传统法规结构正与真实世界数据 (REW) 的快速应用以及对上市后监测的严格要求相辅相成，从而推动了对可扩展分析平台和强大的本地药物安全检测专业知识的需求。在该地区，能够同时应对集中式监管问询和分散式医疗保健资料来源的整合式端到端解决方案更受青睐。

技术深度、治疗领域的专业知识和灵活的交付模式决定了供应商的长期相关性：这是对竞争定位的评估观点。

在药物安全检测领域运作的公司，其竞争基础在于技术能力、领域专业知识以及提供灵活交付模式的能力，以满足客户特定的监管和营运需求。市场领先的机构正在投资模组化分析平台，这些平台支援自动化讯号检测和可配置的工作流程编配，从而能够快速适应申办方的偏好和检查要求。这些投资通常与有针对性的招募和伙伴关係策略相结合，以确保获得能够评估细微因果关係的治疗领域专家和经验丰富的安全医师。

为领导者提供实用、策略性的方法，将高阶分析、混合采购、管治和人才发展整合到强大的药物安全检测计画中。

产业领导者应优先考虑重点策略倡议，以在维持营运韧性的同时提升安全性。首先，应迅速将进阶分析和自然语言处理技术整合到核心监测活动中，以减轻人工负担、提高讯号灵敏度并缩短洞察时间。同时，应建立清晰的检验和管治框架，以确保演算法输出符合监管和临床标准。

严谨的多面向调查方法，结合二手调查、专家访谈、三角检验和情境分析，确保了基于证据的实用见解。

本分析的调查方法结合了多层次的证据收集、检验和整合，以确保其严谨性和实用性。首先，我们进行了一项全面的二手资料调查，涵盖监管指南、同行评审文献和公开的安全通告，以掌握当前的标准、近期政策变化和方法创新。在此基础上，我们开展了有针对性的一手调查，包括对安全官员、监管专家、临床开发主管和供应商进行结构化访谈，以了解实际运作和不断变化的优先事项。

综合分析得出的结论强调了製定综合资料策略、适应性管治和弹性资料收集的必要性。

总之，在分析技术进步、监管预期变化以及商业性和地缘政治压力转变的推动下，药物安全检测正在经历重大变革。那些积极拥抱资料整合、现代化管治和混合交付模式的机构，将更有能力及早发现安全讯号，更果断地做出反应，并维护监管机构和公众的信任。供应链和关税趋势的累积影响凸显了合约韧性和地理分散化在维持专案连续性的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：药物安全检测市场：按类型划分

  • 伫列心臟事件记录器
  • 电子健康记录（EHR）挖掘
  • 增强型ADR报告
  • 自愿报告
  • 有针对性的自愿报告

第九章 依产品生命週期分類的药物安全检测市场

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段
  • 临床前

第十章：药物安全检测市场：以交付方式划分

  • 内部回应
  • 外包

第十一章药物安全检测市场流程分析

  • 案例资料管理
    • 案例数据分析
    • 病例记录
    • 医学审查和报告
  • 风险管理系统
    • 风险评估系统
    • 风险缓解系统
  • 讯号检测
    • 不利事件分析
    • 不利事件记录
    • 不利事件的审查和报告

第十二章药物安全检测市场：依治疗领域划分

  • 循环系统
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 呼吸系统

第十三章药物安全检测市场：依最终用户划分

  • 生技公司
  • 医疗设备製造商
  • 製药公司

第十四章药物安全检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章药物安全检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章药物安全检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国药物安全检测市场

第十八章：中国药物安全检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi SA
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited
Product Code: MRR-43676CF420A3

The Pharmacovigilance Market was valued at USD 11.84 billion in 2025 and is projected to grow to USD 13.71 billion in 2026, with a CAGR of 16.34%, reaching USD 34.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.84 billion
Estimated Year [2026] USD 13.71 billion
Forecast Year [2032] USD 34.17 billion
CAGR (%) 16.34%

A succinct orientation to contemporary pharmacovigilance imperatives reflecting data complexities, regulatory evolution, and organizational readiness for safety governance

Pharmacovigilance sits at the intersection of patient safety, regulatory stewardship, and commercial sustainability. As therapeutic innovation accelerates and real-world evidence gains prominence, safety monitoring paradigms must adapt to more complex data sources, accelerated development timelines, and heightened regulatory scrutiny. This introduction synthesizes the core drivers that are reshaping the discipline, from data architecture and automation to workforce models and cross-functional governance.

Contemporary safety functions are increasingly required to balance rapid signal detection with methodical risk evaluation, while enabling product teams to make timely, evidence-informed decisions. The integration of electronic health records, registries, and patient-reported outcomes is expanding both the volume and heterogeneity of safety inputs, necessitating robust data curation and validation practices. Meanwhile, regulators are signaling expectations for stronger post-market surveillance and risk minimization planning, prompting organizations to re-evaluate roles, workflows, and technology investments.

Transitioning from manual, document-centric approaches to modular, analytics-driven systems is no longer optional for organizations aiming to maintain compliance and competitive differentiation. This introduction establishes the foundational context for the subsequent sections, emphasizing that pragmatic governance, scalable data strategy, and skilled multidisciplinary teams are essential to ensure safety objectives are met across product lifecycles and global markets.

An exploration of the major structural and technological shifts redefining pharmacovigilance operations including AI, real-world evidence, and modern regulatory expectations

The pharmacovigilance landscape is experiencing transformative shifts driven by technological innovation, regulatory modernization, and strategic sourcing. Artificial intelligence and machine learning are enabling earlier identification of safety signals through pattern recognition across disparate datasets, while natural language processing improves the extraction of relevant information from free-text sources such as medical notes and social media. These capabilities are complemented by maturing real-world data ecosystems that allow safety teams to augment traditional clinical trial evidence with longitudinal patient information.

Concurrently, regulators are evolving expectations for transparency, proactive risk management, and the incorporation of real-world evidence into safety decision-making. This regulatory momentum is prompting organizations to move beyond compliance checklists and toward continuous evidence generation frameworks that emphasize lifecycle safety. Operationally, many safety organizations are adopting hybrid delivery models that combine in-house expertise for strategic oversight with outsourced capabilities for scale and specialized analytics, enabling rapid ramp-up during peak activities.

Culturally, cross-functional integration of pharmacovigilance with clinical development, regulatory affairs, and commercial teams is becoming essential to accelerate time-to-decision and to design pragmatic risk mitigation strategies. As a result, leaders are investing in change management, upskilling, and formalized governance to ensure that new tools and data sources are leveraged responsibly and effectively. Together, these shifts redefine what it means to deliver high-quality patient safety in an increasingly dynamic therapeutic and regulatory environment.

A comprehensive assessment of how 2025 tariff measures have reshaped supply chain choices, outsourcing strategies, and cost governance across pharmacovigilance operations

The introduction of enhanced tariffs in 2025 has produced a cascade of operational and strategic responses across the pharmacovigilance ecosystem, affecting supply chains, service procurement, and cost structures. Increased duties on imported goods have elevated the cost base for certain medical devices and supporting hardware, prompting some organizations to re-evaluate capital procurement timing and to consider localized sourcing to reduce exposure to cross-border levies. These procurement pressures have indirect implications for pharmacovigilance, especially where instrument-driven diagnostics or third-party safety hardware are part of surveillance workflows.

In addition, tariff-driven cost inflation has influenced outsourcing decisions. Some sponsors have shifted to more geographically balanced outsourcing arrangements, favoring service providers with delivery centers in regions with lower tariff exposure or with established nearshore capabilities. This redistribution aims to preserve budget flexibility for data analytics investments while maintaining capacity for case processing, medical review, and query management. At the same time, vendor contracts are being renegotiated to include clauses that address tariff volatility, cost pass-through, and contingency staffing to preserve continuity of safety operations.

Regulatory compliance budgets have also felt downstream effects. Organizations are prioritizing investments that directly enhance signal detection and regulatory responsiveness, given the operational constraints imposed by tariff-related cost pressures. Overall, the cumulative impact of the 2025 tariff changes has accelerated strategic localization of supply and delivery, strengthened contractual risk management, and intensified the focus on efficiency improvements across pharmacovigilance processes to preserve program resilience and patient safety outcomes.

In-depth segmentation analysis revealing how safety methodology, lifecycle stage, delivery models, process architecture, therapeutic focus, and end-user profiles shape pharmacovigilance priorities

Key segmentation insights reveal differentiated strategic priorities across methods of safety capture, clinical development stages, delivery models, process architecture, therapeutic focus, and end-user types. When considering Type, approaches such as Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting each impose distinct data quality, latency, and validation requirements; Cohort Event Monitoring and EHR Mining demand strong longitudinal data linkage and advanced analytics, while Spontaneous Reporting emphasizes rapid intake and standardized coding workflows.

Considering Product Life Cycle, requirements vary significantly across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical stages. Early phases prioritize safety signal characterization and close medical oversight, whereas Phase IV activities emphasize long-term risk minimization and integration of post-market surveillance data. Delivery Mode also dictates capability design: In-house models support strategic oversight, knowledge retention, and direct regulatory interface, while Outsourced models provide scalability, specialized expertise, and cost flexibility during peak activity windows.

Process Flow segmentation highlights distinct operational foci across Case Data Management, Risk Management System, and Signal Detection. Case Data Management encompasses case data analysis, case logging, and medical reviewing and reporting, requiring robust case-tracking, quality control, and therapeutic expertise. The Risk Management System incorporates risk evaluation system and risk mitigation system capabilities that support lifecycle risk assessment and the implementation of targeted interventions. Signal Detection functions involve adverse event analysis, adverse event logging, and adverse event review and reporting, relying on statistical monitoring, data harmonization, and multidisciplinary adjudication.

Therapeutic Area segmentation-spanning cardiovascular, infectious diseases, neurology, oncology, and respiratory-shapes the expected event typologies, monitoring cadence, and specialist expertise required for accurate causality assessment. End-user distinctions among biotechnology companies, medical device manufacturers, and pharmaceuticals influence contracting models, acceptable risk-tolerance thresholds, and the degree of regulatory engagement expected, with each end-user type balancing speed to insight against the need for rigorous medical and regulatory evidence.

A regional appraisal of how jurisdictional variation in regulation, data infrastructure, and service capabilities demands integrated global standards with localized execution strategies

Regional dynamics materially influence operational design, regulatory strategy, and resourcing decisions across jurisdictions. In the Americas, legacy regulatory frameworks are being augmented by accelerated adoption of real-world evidence and robust post-market surveillance expectations, driving demand for scalable analytics platforms and strong local pharmacovigilance expertise. This region favors integrated end-to-end solutions that can respond to both centralized regulatory inquiries and decentralized healthcare data sources.

Across Europe, Middle East & Africa, heterogeneity in regulatory maturities requires adaptable engagement strategies. The European regulatory environment places emphasis on transparency, data protection, and cross-border pharmacovigilance cooperation, while markets in the Middle East and Africa present variable infrastructure and data availability that often necessitate hybrid approaches combining centralized analytics with targeted local studies. Consequently, organizations operating in this broad region must balance pan-regional standardization with localized execution flexibility.

The Asia-Pacific landscape is characterized by rapid adoption of digital health technologies, growing clinical trial activity, and an expanding pool of specialized service providers. Diverse regulatory regimes in the region create opportunities for nearshore delivery models and regional hubs that provide cost efficiency and time zone alignment for sponsors. Together, these regional insights suggest that successful pharmacovigilance strategies require a mosaic approach: harmonized global standards layered with regionally tailored processes and partnerships that reflect local regulatory expectations, data ecosystems, and operational readiness.

An evaluative perspective on competitive positioning where technological depth, therapeutic expertise, and flexible delivery models determine long-term vendor relevance

Companies operating in the pharmacovigilance space are competing on the basis of technological capability, domain expertise, and the ability to deliver flexible delivery models that meet client-specific regulatory and operational needs. Market-leading organizations are investing in modular analytics platforms that support both automated signal detection and configurable workflow orchestration, enabling rapid adaptation to sponsor preferences and inspection requirements. These investments are frequently paired with focused recruitment or partnership strategies to secure therapeutic-area specialists and experienced safety physicians capable of nuanced causality assessment.

Strategic partnerships between technology providers, contract safety organizations, and data custodians are increasingly common, enabling bundled offerings that combine data access, analytics, and case processing at scale. At the same time, nimble boutique providers differentiate through deep therapeutic expertise or specialized services such as intensified ADR reporting programs, targeted spontaneous reporting frameworks, and bespoke risk evaluation systems. Buyers are scrutinizing vendor governance structures, evidence of regulatory inspection readiness, and demonstrable outcomes such as cycle-time reductions and improvements in signal-to-noise ratios.

Competitive positioning is also influenced by geographic delivery footprint and the ability to provide hybrid in-house and outsourced models that align with client risk tolerances. Companies that can demonstrate robust quality systems, transparent pricing models, and agile implementation methodologies are most likely to secure long-term partnerships as sponsors prioritize reliability, scalability, and the capacity to integrate emerging data streams into established pharmacovigilance processes.

Actionable strategic initiatives for leaders to embed advanced analytics, hybrid sourcing, governance, and workforce development into robust pharmacovigilance programs

Industry leaders should prioritize a focused set of strategic initiatives to strengthen safety outcomes while maintaining operational resilience. First, accelerate integration of advanced analytics and natural language processing into core surveillance activities to reduce manual effort, increase signal sensitivity, and shorten time-to-insight. Simultaneously, establish clear validation and governance frameworks to ensure algorithmic outputs meet regulatory and clinical standards.

Second, adopt a hybrid sourcing strategy that combines in-house leadership for critical judgment functions with outsourced scale for routine processing and specialized analytics. This approach preserves institutional knowledge while enabling rapid capacity management during clinical accelerations or post-market demands. Third, cultivate cross-functional governance that embeds pharmacovigilance metrics into development decision-making, regulatory planning, and commercial strategy to ensure safety considerations are factored into lifecycle choices.

Fourth, invest in workforce development to upskill safety professionals in data science, regulatory intelligence, and evidence synthesis, thereby enhancing the team's ability to interpret complex signals and to communicate decisions to stakeholders. Fifth, design contractual safeguards with vendors to manage geopolitical and tariff-related risks, including clauses for cost adjustment, contingency staffing, and data sovereignty. By implementing these focused actions, organizations can enhance their ability to detect and mitigate risks, preserve compliance, and sustain trust among providers, payers, and patients.

A rigorous multi-method research approach combining secondary review, expert interviews, triangulation, and scenario analysis to ensure evidence-based and pragmatic insights

The research methodology underpinning this analysis combined a layered approach to evidence gathering, validation, and synthesis to ensure rigor and practical relevance. The process began with comprehensive secondary research encompassing regulatory guidance, peer-reviewed literature, and public domain safety communications to map current standards, recent policy shifts, and methodological innovations. This foundation informed targeted primary research involving structured interviews with safety leaders, regulatory specialists, clinical development executives, and vendors to capture operational realities and evolving priorities.

Data triangulation techniques were applied to reconcile divergent perspectives, with scenario-based analyses used to stress-test strategic responses against variables such as tariff shifts, regional regulatory changes, and rapid adoption of new data sources. Quality control included methodological audits, cross-validation of key assertions with independent domain experts, and iterative review cycles to ensure factual accuracy and practical applicability. Wherever analytic models were used to illustrate process implications, they were accompanied by sensitivity examinations to highlight key assumptions and to delineate areas requiring further empirical validation.

This multi-method approach was designed to deliver findings that are both evidence-based and pragmatically oriented, supporting leaders in translating strategic insight into operational decisions while accounting for the inherent complexity of global pharmacovigilance ecosystems.

A concluding synthesis emphasizing the necessity of integrated data strategies, adaptive governance, and resilient sourcing to secure sustained pharmacovigilance excellence

In conclusion, pharmacovigilance is undergoing substantive transformation driven by advances in analytics, shifts in regulatory expectations, and evolving commercial and geopolitical pressures. Organizations that embrace data integration, governance modernization, and hybrid delivery models will be better positioned to detect safety signals earlier, to respond more decisively, and to maintain regulatory and public trust. The cumulative effects of supply chain and tariff dynamics underscore the importance of contractual resilience and geographic diversification in sustaining program continuity.

The segmentation and regional analyses highlight that there is no single operational model that fits all contexts; instead, successful programs align methodological choices with lifecycle stage, therapeutic complexity, and end-user priorities. Competitive advantage will accrue to organizations that combine technological investments with domain expertise and agile operating models. Ultimately, pharmacovigilance must be treated as a strategic capability that protects patients while enabling therapeutic innovation, and the pathway to that capability requires deliberate investments in people, process, and technology.

Leaders should view the recommendations and insights in this report as a practical blueprint for action: prioritize analytics and governance, refine sourcing strategies, and invest in the workforce to sustain high-quality safety outcomes in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacovigilance Market, by Type

  • 8.1. Cohort Event Monitoring
  • 8.2. EHR Mining
  • 8.3. Intensified ADR Reporting
  • 8.4. Spontaneous Reporting
  • 8.5. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by Product Life Cycle

  • 9.1. Phase I
  • 9.2. Phase II
  • 9.3. Phase III
  • 9.4. Phase IV
  • 9.5. Pre-clinical

10. Pharmacovigilance Market, by Delivery Mode

  • 10.1. In-house
  • 10.2. Outsourced

11. Pharmacovigilance Market, by Process Flow

  • 11.1. Case Data Management
    • 11.1.1. Case Data Analysis
    • 11.1.2. Case Logging
    • 11.1.3. Medical Reviewing & Reporting
  • 11.2. Risk Management System
    • 11.2.1. Risk Evaluation System
    • 11.2.2. Risk Mitigation System
  • 11.3. Signal Detection
    • 11.3.1. Adverse Event Analysis
    • 11.3.2. Adverse Event Logging
    • 11.3.3. Adverse Event Review & Reporting

12. Pharmacovigilance Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Infectious Diseases
  • 12.3. Neurology
  • 12.4. Oncology
  • 12.5. Respiratory

13. Pharmacovigilance Market, by End-user

  • 13.1. Biotechnology Companies
  • 13.2. Medical Device Manufacturers
  • 13.3. Pharmaceuticals

14. Pharmacovigilance Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Pharmacovigilance Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pharmacovigilance Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Pharmacovigilance Market

18. China Pharmacovigilance Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accenture, PLC
  • 19.6. Bristol-Myers Squibb Company
  • 19.7. Capgemini SE
  • 19.8. ClinChoice
  • 19.9. F. Hoffmann-La Roche AG
  • 19.10. GlaxoSmithKline PLC
  • 19.11. HCL Technologies Limited
  • 19.12. ICON PLC
  • 19.13. Infosys Limited
  • 19.14. International Business Machines Corporation
  • 19.15. IQVIA Inc.
  • 19.16. ITclinical
  • 19.17. Laboratory Corporation of America Holdings
  • 19.18. Linical Co., Ltd.
  • 19.19. Novartis AG
  • 19.20. Oracle Corporation
  • 19.21. Parexel International
  • 19.22. Pfizer Inc.
  • 19.23. Quanticate International limited
  • 19.24. Sanofi S.A.
  • 19.25. Syneos Health
  • 19.26. TAKE Solutions Limited
  • 19.27. TATA Consultancy Services Limited
  • 19.28. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 231. G7 PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 232. G7 PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 233. G7 PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. G7 PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 242. NATO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 243. NATO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 244. NATO PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 245. NATO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PHARMACOVIGILANCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)